GO:0097718 disordered domain specific binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097718 (disordered domain specific binding) is a molecular function defined as binding to a disordered domain of a protein [QuickGO].
• Intrinsically disordered regions (IDRs) lack fixed 3D structure yet mediate highly specific protein-protein and protein-DNA interactions.
• Disordered domain binding can tune binding affinity, temperature dependence, and specificity of transcription factors and chromatin remodelers.
• Disease relevance spans Menke-Hennekam syndrome (CREBBP/EP300), cancers driven by BAF complex retargeting, and androgen receptor signaling.
• Key experimental approaches include CRISPR knockout, point mutation, knock-in tagging, and overexpression of IDR-containing proteins.
• EDITGENE provides end-to-end CRISPR cell model services to dissect disordered domain specific binding in disease and drug discovery.
Description
GO:0097718, disordered domain specific binding, is a molecular function term in the Gene Ontology that describes the selective binding of a protein or other molecule to a disordered domain of a target protein [QuickGO]. Disordered domains, often called intrinsically disordered regions (IDRs), lack a stable three-dimensional fold yet frequently serve as hubs for protein-protein interactions, allosteric regulation, and signal integration. Understanding this binding mode is essential because it challenges the classical structure-function paradigm and reveals how specificity can emerge from conformational ensembles rather than rigid lock-and-key interfaces. Researchers study disordered domain specific binding to explain how transcription factors, chromatin remodelers, and signaling scaffolds achieve precise partner selection under physiological conditions. Disordered regions can also modulate the temperature dependence of binding free energies, which has implications for cellular robustness and disease. This article synthesizes authoritative QuickGO annotation with verified PubMed literature to provide a research-grade overview of GO:0097718, its mechanisms, associated genes, disease links, and CRISPR-based experimental strategies.
disordered domain specific binding At A Glance
| GO ID | GO:0097718 |
|---|---|
| GO term | disordered domain specific binding |
| Ontology | molecular_function |
| Synonym | disordered protein domain specific binding |
| Major function | Selective binding to intrinsically disordered regions of proteins, enabling specific protein-protein or protein-nucleic acid interactions |
| Related concepts | Intrinsically disordered regions (IDRs), short linear motifs (SLiMs), conformational ensembles, allostery |
| Disease examples | Menke-Hennekam syndrome, BAF complex-driven cancers, androgen receptor-related disorders |
| Experimental models | CRISPR knockout, point mutation, knock-in tagging, overexpression |
What Is GO:0097718?
According to the Gene Ontology, GO:0097718 (disordered domain specific binding) is defined as binding to a disordered domain of a protein [QuickGO]. In other words, it is the molecular function of selectively recognizing and physically associating with a protein region that lacks a fixed tertiary structure. This binding event can involve short linear motifs, charge patches, or hydrophobic clusters within an IDR, and it often occurs with moderate affinity and high specificity. The synonym disordered protein domain specific binding is also used [QuickGO].
Why Is disordered domain specific binding Important in Cell Biology?
Disordered domain specific binding is important because a large fraction of eukaryotic proteins contain intrinsically disordered regions, and these regions are disproportionately involved in signaling, transcription, and disease. Unlike folded domains, IDRs can bind multiple partners with varying affinities and can be regulated by post-translational modifications, making them central to cellular decision-making. Mutations or dysregulation of disordered domain interactions are increasingly linked to developmental syndromes and cancer, as exemplified by CREBBP/EP300 in Menke-Hennekam syndrome and BAF complex retargeting in cancer. Studying GO:0097718 therefore provides mechanistic insight into both normal physiology and disease pathogenesis.
• Disordered domains enable specific binding without a fixed structure, expanding the functional repertoire of the proteome.
• They modulate the temperature dependence of binding free energies, affecting cellular robustness.
• Unstructured transcription factor interactions can generate emergent specificity in gene regulation.
• Disordered regions in NFκB p50/RelA alter DNA binding affinity and specificity.
• The androgen receptor N-terminal domain allosterically controls DNA binding.
• Prion-like domains can retarget BAF chromatin remodeling complexes in cancer.
• Mutations in CREBBP/EP300 disordered regions cause Menke-Hennekam syndrome.
• Disordered domain binding is a potential target for therapeutic intervention in cancer and developmental disorders.
• CRISPR-based models allow precise dissection of disordered domain function in vivo.
• Understanding GO:0097718 informs drug discovery for undruggable disordered targets.
Molecular Mechanism of disordered domain specific binding
Recognition of disordered domains
In simple terms: A protein recognizes a flexible, unstructured region of another protein.
Disordered domain specific binding begins with the recognition of an intrinsically disordered region (IDR) by a binding partner. Unlike folded domains, IDRs sample multiple conformations, and binding often involves coupled folding and binding or fuzzy complexes. This recognition can be mediated by short linear motifs, charge complementarity, or hydrophobic interactions, and it enables high specificity despite low structural order.
Conformational selection and induced fit
In simple terms: The disordered region changes shape when it binds, like a hand fitting into a glove.
Binding to disordered domains can proceed via conformational selection, where a pre-existing IDR conformation is captured, or induced fit, where the IDR folds upon contact. These mechanisms influence binding affinity, kinetics, and temperature dependence. For example, disordered proteins can mitigate the temperature dependence of site-specific binding free energies, contributing to thermal robustness.
Allosteric regulation by disordered domains
In simple terms: Binding to a disordered region can change how another part of the protein works.
Disordered domains can allosterically regulate the function of folded domains. In the androgen receptor, the disordered N-terminal domain controls DNA binding by the DNA-binding domain, demonstrating long-range allosteric coupling. Similarly, the disordered transcription activation domain of NFκB p50/RelA increases DNA binding affinity while reducing specificity, illustrating how IDRs can tune both affinity and selectivity.
Emergent specificity in transcription factor interactions
In simple terms: Unstructured regions help transcription factors choose the right partners.
Unstructured transcription factor interactions can enable emergent specificity, where the combination of multiple weak interactions yields precise partner selection. This is particularly important in gene regulatory networks, where disordered domains allow transcription factors to integrate signals and discriminate among closely related partners.
Pathological retargeting by disordered domains
In simple terms: When disordered domains go wrong, they can send proteins to the wrong places.
Disordered domains can become drivers of disease when mutations or aberrant interactions retarget them. For instance, a prion-like domain in a BAF complex subunit can retarget the complex to oncogenic enhancers in cancer. In Menke-Hennekam syndrome, mutations in the disordered regions of CREBBP/EP300 alter domain-specific functions and DNA methylation profiles.
Key Genes Involved in GO:0097718 disordered domain specific binding
The following genes and proteins are experimentally implicated in disordered domain specific binding (GO:0097718) based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CREBBP | Contains disordered regions; mutations cause Menke-Hennekam syndrome | Developmental disorder modeling; domain-specific subtype analysis |
| EP300 | Paralog of CREBBP with disordered domains; mutated in Menke-Hennekam syndrome | Comparative studies of domain-specific effects |
| AR | Androgen receptor N-terminal disordered domain allosterically controls DNA binding | Prostate cancer and androgen insensitivity research |
| NFKB1 | NFκB p50 subunit with disordered regions affecting DNA binding | Inflammation and transcription specificity studies |
| RELA | NFκB RelA transcription activation domain is disordered and modulates DNA binding | NFκB signaling and drug discovery |
| BAF complex subunits (e.g., ARID1A) | Prion-like domains can retarget BAF complexes in cancer | Cancer epigenetics and chromatin remodeling |
| CaLB | C2 domain protein with membrane-specific and calcium-dependent binding | Plant signaling and lipid binding studies |
| IL-12 | Collagen-binding IL-12 fusion exploits disordered collagen-binding domain | Cancer immunotherapy models |
| TP53 | Contains disordered regions; often mutated in cancer | Cancer biology and IDR-targeted therapy |
| MYC | Disordered transcription factor with emergent specificity | Oncogene regulation and transcription studies |
| JUN | Disordered transcription factor interactions | AP-1 signaling research |
| FOS | Disordered transcription factor interactions | AP-1 signaling research |
| ESR1 | Estrogen receptor with disordered domains | Breast cancer and endocrine therapy |
| CTNNB1 | Beta-catenin with disordered regions | Wnt signaling and cancer |
| SMAD4 | Disordered regions in TGF-beta signaling | Developmental and cancer signaling |
| HIF1A | Disordered oxygen-dependent degradation domain | Hypoxia signaling research |
| STAT3 | Disordered transactivation domain | JAK-STAT signaling and cancer |
How Is disordered domain specific binding Regulated?
Disordered domain specific binding is regulated at multiple levels. Post-translational modifications such as phosphorylation, acetylation, and methylation can alter the charge and hydrophobicity of IDRs, thereby modulating binding affinity and specificity. Allosteric coupling between disordered and folded domains, as seen in the androgen receptor, provides another layer of regulation. Additionally, mutations in disordered regions can disrupt or retarget binding, as observed in Menke-Hennekam syndrome and BAF complex-driven cancers. The temperature dependence of binding free energies also suggests that environmental factors such as temperature can influence disordered domain interactions.
disordered domain specific binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CREBBP | Menke-Hennekam syndrome | CRISPR knock-in of patient mutations in cell lines |
| EP300 | Menke-Hennekam syndrome | CRISPR knockout and point mutation models |
| AR | Prostate cancer, androgen insensitivity | CRISPR point mutation of N-terminal domain |
| BAF complex subunits | Cancer epigenetics | CRISPR knockout and overexpression of prion-like domain |
| RELA | Inflammatory diseases | CRISPR knockout and tagged knock-in for imaging |
Menke-Hennekam syndrome and CREBBP/EP300 disordered domains
Menke-Hennekam syndrome is a developmental disorder caused by mutations in CREBBP or EP300, many of which fall within disordered regions. Domain-specific subtypes show distinct clinical and DNA methylation profiles, highlighting how disordered domain specific binding contributes to disease heterogeneity. Studying these mutations using CRISPR knock-in models can reveal how disordered domain dysfunction leads to developmental phenotypes.
Cancer and BAF complex retargeting
Disordered prion-like domains can retarget the BAF chromatin remodeling complex to oncogenic enhancers, driving cancer-specific gene expression programs. This exemplifies how disordered domain specific binding can be hijacked in malignancy. Targeting these interactions with CRISPR-based screens may identify vulnerabilities in BAF-mutant cancers.
Androgen receptor signaling in prostate cancer
The androgen receptor N-terminal disordered domain allosterically controls DNA binding, influencing transcriptional programs in prostate cancer. Mutations or alterations in this disordered domain can affect androgen sensitivity and resistance to therapy. CRISPR point mutation models can dissect the contribution of specific residues within the disordered domain.
NFκB and inflammatory diseases
The disordered transcription activation domain of NFκB p50/RelA increases DNA binding affinity while reducing specificity, which can lead to aberrant inflammatory gene expression. Understanding how disordered domain specific binding shapes NFκB target selection may inform therapies for inflammatory diseases.
From disordered domain specific binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CREBBP disordered domain cause Menke-Hennekam phenotypes? | CRISPR knockout or knock-in of patient mutations |
| How does AR N-terminal domain allosterically regulate DNA binding? | CRISPR point mutation of key residues |
| Can BAF complex retargeting be reversed by disrupting prion-like domain? | CRISPR knockout of prion-like domain |
| What is the role of NFκB disordered domain in DNA binding specificity? | CRISPR knock-in of tagged RelA |
| How do disordered domains affect temperature-dependent binding? | Overexpression of IDR-containing proteins |
| Can disordered domain interactions be targeted therapeutically? | CRISPR library screening for modifiers |
How to Study the disordered domain specific binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screens | Gene essentiality and modifier identification | Discovering disordered domain dependencies |
| Isothermal titration calorimetry | Binding affinity and thermodynamics | Quantifying IDR binding |
| NMR spectroscopy | Conformational dynamics of IDRs | Characterizing disordered domain ensembles |
| ATR-FTIR | Secondary structure and membrane binding | Studying C2 domain-lipid interactions |
| ChIP-seq | DNA binding sites of transcription factors | Mapping NFκB and AR binding |
| RNA-seq | Transcriptional changes | Assessing downstream effects of IDR mutations |
| DNA methylation profiling | Epigenetic signatures | Subtyping Menke-Hennekam syndrome |
| Surface plasmon resonance | Real-time binding kinetics | Measuring disordered domain interactions |
CRISPR-based genetic screens
CRISPR knockout and activation screens can identify genes whose disordered domains modulate specific binding events. For example, screens targeting chromatin remodelers can reveal how prion-like domains retarget BAF complexes in cancer. These screens are powerful for unbiased discovery of disordered domain functions.
Biochemical binding assays
Isothermal titration calorimetry, surface plasmon resonance, and fluorescence polarization can measure binding affinities and kinetics of disordered domain interactions. Such assays have been used to study the temperature dependence of binding free energies for disordered proteins and the allosteric control of androgen receptor DNA binding.
Structural and spectroscopic methods
Nuclear magnetic resonance (NMR), circular dichroism, and ATR-FTIR spectroscopy can characterize the conformational ensembles of disordered domains and their changes upon binding. ATR-FTIR has been used to study membrane-specific and calcium-dependent binding of the Arabidopsis C2 domain protein CaLB.
Functional genomics and epigenomics
RNA-seq, ChIP-seq, and DNA methylation profiling can reveal the downstream consequences of disordered domain mutations. For instance, distinct DNA methylation profiles are associated with domain-specific subtypes of Menke-Hennekam syndrome. These methods link disordered domain specific binding to gene expression and epigenetic states.
How CRISPR Can Be Used to Study GO:0097718 disordered domain specific binding
Knockout
CRISPR knockout of genes encoding disordered domain-containing proteins can reveal loss-of-function phenotypes. For example, knocking out CREBBP or EP300 in cell models can mimic Menke-Hennekam syndrome and help identify domain-specific functions. Knockout of BAF complex subunits can disrupt chromatin remodeling and cancer cell proliferation.
Point Mutation
CRISPR point mutation allows precise editing of residues within disordered domains to test their role in binding. This is particularly useful for studying allosteric regulation, such as in the androgen receptor N-terminal domain. Point mutations can also model patient-specific variants in CREBBP/EP300.
Knock-in
Knock-in of tagged or mutant disordered domains enables tracking and functional analysis. For instance, knocking in a fluorescent tag into RELA can visualize NFκB dynamics and DNA binding. Knock-in of patient mutations in CREBBP can model Menke-Hennekam syndrome in isogenic cell lines.
Overexpression
Overexpression of disordered domain-containing proteins or isolated IDRs can test gain-of-function effects and dominant-negative interactions. Overexpression of prion-like domains can retarget BAF complexes and drive oncogenic transcription. Overexpression of NFκB subunits can alter DNA binding specificity.
How EDITGENE Supports disordered domain specific binding Research
Researchers studying disordered domain specific binding-related genes often need to determine whether a candidate gene is causally involved in a phenotype, and CRISPR-based cell models provide a rigorous way to establish causality. EDITGENE offers a comprehensive suite of services to generate precisely engineered cell lines for such studies.
Contact EDITGENE today to design your custom CRISPR model for disordered domain specific binding research.
Frequently Asked Questions About disordered domain specific binding
What is GO:0097718?
GO:0097718 is a Gene Ontology molecular function term defined as binding to a disordered domain of a protein [QuickGO].
What is disordered domain specific binding?
It is the selective binding of a molecule to an intrinsically disordered region of a protein, often involving conformational changes and enabling specific interactions.
What genes are involved in disordered domain specific binding?
Genes such as CREBBP, EP300, AR, NFKB1, RELA, and BAF complex subunits encode proteins with disordered domains that participate in this function.
How does disordered domain binding affect transcription?
Disordered domains can increase DNA binding affinity, reduce specificity, and enable emergent specificity in transcription factor interactions.
What diseases are linked to disordered domain specific binding?
Menke-Hennekam syndrome, cancers driven by BAF complex retargeting, prostate cancer, and inflammatory diseases are linked to disordered domain interactions.
How can CRISPR be used to study disordered domain specific binding?
CRISPR knockout, point mutation, knock-in, and overexpression can precisely perturb disordered domains to test their function in cells.
What methods measure disordered domain binding?
Isothermal titration calorimetry, surface plasmon resonance, NMR, and ATR-FTIR spectroscopy are commonly used.
Why are disordered domains important in cancer?
Disordered domains can retarget chromatin remodelers like BAF complexes to oncogenic enhancers, driving cancer-specific gene expression.
What is the role of the androgen receptor N-terminal domain?
The disordered N-terminal domain allosterically controls DNA binding by the androgen receptor, influencing transcriptional programs.
How does EDITGENE support disordered domain research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics services for disordered domain studies.
Conclusion
GO:0097718 (disordered domain specific binding) represents a fundamental molecular function that underlies many critical protein-protein and protein-nucleic acid interactions. Disordered domains enable specificity, allostery, and environmental responsiveness, and their dysregulation is implicated in developmental syndromes and cancer. Continued research using CRISPR-based models and advanced biophysical methods will further illuminate how disordered domains shape cellular function and disease. EDITGENE is committed to supporting this research with tailored cell model and screening services.
References
- 1. Haghshenas S et al.. 2024. Menke-Hennekam syndrome; delineation of domain-specific subtypes with distinct clinical and DNA methylation profiles.. HGG Adv 5(3):100287 PMID: 38553851
- 2. Thole JF et al.. 2023. Disordered proteins mitigate the temperature dependence of site-specific binding free energies.. J Biol Chem 299(3):102984 PMID: 36739945
- 3. Abidi AA et al.. 2026. Unstructured transcription factor interactions enable emergent specificity.. Science 392(6801):eaeb6487 PMID: 41855276
- 4. Maguire S et al.. 2024. Membrane-specific and calcium-dependent binding of the Arabidopsis C2 domain protein CaLB revealed by ATR-FTIR spectroscopy.. Spectrochim Acta A Mol Biomol Spectrosc 307:123629 PMID: 37995652
- 5. Boulay G et al.. 2017. Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain.. Cell 171(1):163-178.e19 PMID: 28844694
- 6. Heling LWHJ et al.. 2025. Deciphering the allosteric control of androgen receptor DNA binding by its disordered N-terminal domain.. Mol Cell Endocrinol 608:112634 PMID: 40782996
- 7. Mansurov A et al.. 2020. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours.. Nat Biomed Eng 4(5):531-543 PMID: 32284554
- 8. Baughman HER et al.. 2022. An intrinsically disordered transcription activation domain increases the DNA binding affinity and reduces the specificity of NFκB p50/RelA.. J Biol Chem 298(9):102349 PMID: 35934050
